Merck: Anacetrapib misses statistical significance in study.
(CercleFinance.com) - American pharma giant Merck's cholesterol-lowering medicine Anacetrapib has failed to make a statistically significant difference in reducing cardiovascular diseases in a study, the company said on Tuesday.
The results, which were published in The New England Journal of Medicine, and presented at the European Society of Cardiology Congress in Barcelona, showed that the drug reduced the risk of major coronary events (coronary death, myocardial infarction or coronary revascularization) by 9% relative to placebo.
However, the drug did not reach the level of statistical significance, the New Jersey-based company said.
After this trial, which enrolled 30,449 patients with atherosclerotic vascular disease, Merck is reviewing the results with experts and will consider whether to file new drug applications with the US Food and Drug Administration (FDA) and other agencies.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The results, which were published in The New England Journal of Medicine, and presented at the European Society of Cardiology Congress in Barcelona, showed that the drug reduced the risk of major coronary events (coronary death, myocardial infarction or coronary revascularization) by 9% relative to placebo.
However, the drug did not reach the level of statistical significance, the New Jersey-based company said.
After this trial, which enrolled 30,449 patients with atherosclerotic vascular disease, Merck is reviewing the results with experts and will consider whether to file new drug applications with the US Food and Drug Administration (FDA) and other agencies.
Copyright (c) 2017 CercleFinance.com. All rights reserved.